Synergistic drug combinations explored for systemic sclerosis vasodilation

It is known that vasculopathy plays a pivotal role in the pathogenesis of systemic sclerosis (SSc). Vasoactive vasodilating drugs (VVD) are an option. The most recent treatment recommendations from EULAR—The European Alliance of Associations for Rheumatology—note that advances in vasculopathy management for patients with SSc emphasize a treatment continuum for the use of various VVD, but also stress the need for trials to look for potential synergistic combinations as well as high-quality real-world data to build the evidence. New data shared at the 2025 EULAR congress in Barcelona may take a step in that direction.

👉 Full Story